New Perspectives on Diagnosis and Treatment of EGFR Exon 20 Insertion-Mutant NSCLC

Free CME and NCPD credit are available for this podcast. To claim credit, visit i3health.com/oda-EGFR-exon20-NSCLC. EGFR exon 20 insertion mutations are associated with a worse prognosis than other types of EGFR-mutant non-small cell lung cancer, or NSCLC. This episode of Oncology Data Advisor will focus on new developments in the diagnosis and treatment of NSCLC with EGFR exon 20 insertion mutations. It features perspectives from two noted experts in the field: Dr. Helena Yu, Assistant Attending Physician at Memorial Sloan Kettering Cancer Center; and Dr. Maria Arcila, Director of the Diagnostic Molecular Pathology Laboratory at Memorial Sloan Kettering Cancer Center. This activity is supported by an educational grant from Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.